INT95207

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.58
First Reported 2001
Last Reported 2010
Negated 0
Speculated 2
Reported most in Body
Documents 46
Total Number 47
Disease Relevance 32.01
Pain Relevance 10.14

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (Pde5a) signal transduction (Pde5a)
Anatomy Link Frequency
lung 3
liver 2
paw 1
heart 1
hippocampus 1
Pde5a (Mus musculus)
Pain Link Frequency Relevance Heat
depression 65 99.92 Very High Very High Very High
agonist 18 99.90 Very High Very High Very High
Morphine 7 99.76 Very High Very High Very High
Antinociceptive 9 99.70 Very High Very High Very High
analgesia 8 99.58 Very High Very High Very High
Restless leg syndrome 13 99.52 Very High Very High Very High
Inflammation 582 99.46 Very High Very High Very High
Hyperalgesia 11 99.08 Very High Very High Very High
antagonist 16 99.04 Very High Very High Very High
fibrosis 15 98.40 Very High Very High Very High
Disease Link Frequency Relevance Heat
Depression 65 99.92 Very High Very High Very High
Pulmonary Hypertension 606 99.84 Very High Very High Very High
Nociception 18 99.84 Very High Very High Very High
Increased Venous Pressure Under Development 89 99.52 Very High Very High Very High
INFLAMMATION 607 99.46 Very High Very High Very High
Targeted Disruption 105 99.34 Very High Very High Very High
Reprotox - General 2 98 99.08 Very High Very High Very High
Hyperalgesia 15 99.08 Very High Very High Very High
Pulmonary Fibrosis 13 98.80 Very High Very High Very High
Hypersensitivity 74 98.64 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
IC351 (Cialis) is a selective inhibitor of PDE5.
Negative_regulation (inhibitor) of PDE5
1) Confidence 0.58 Published 2001 Journal Int. J. Impot. Res. Section Abstract Doc Link 11313831 Disease Relevance 0.17 Pain Relevance 0
PDE5A inhibition attenuates bleomycin-induced pulmonary fibrosis and pulmonary hypertension through inhibition of ROS generation and RhoA/Rho kinase activation.
Negative_regulation (inhibition) of PDE5A associated with fibrosis, pulmonary hypertension and pulmonary fibrosis
2) Confidence 0.57 Published 2008 Journal Am. J. Physiol. Lung Cell Mol. Physiol. Section Title Doc Link 17965319 Disease Relevance 0.79 Pain Relevance 0.11
Vardenafil is a commercially available PDE-5 inhibitor used for the treatment of erectile dysfunction that is not FDA approved for the treatment of PAH.


Negative_regulation (inhibitor) of PDE-5 associated with reprotox - general 2 and pulmonary hypertension
3) Confidence 0.57 Published 2010 Journal Drug design, development and therapy Section Body Doc Link PMC2880338 Disease Relevance 0.86 Pain Relevance 0.03
These results suggest that sildenafil-induced analgesia is mediated via the inhibition of PDE5.
Negative_regulation (inhibition) of PDE5 associated with analgesia
4) Confidence 0.52 Published 2001 Journal Brain Res. Section Abstract Doc Link 11478933 Disease Relevance 0.47 Pain Relevance 0.84
Tadalafil is an orally administered PDE-5 inhibitor currently approved for treatment erectile dysfunction and PAH.
Negative_regulation (inhibitor) of PDE-5 associated with reprotox - general 2 and pulmonary hypertension
5) Confidence 0.50 Published 2010 Journal Drug design, development and therapy Section Body Doc Link PMC2880338 Disease Relevance 1.02 Pain Relevance 0
INTRODUCTION: Vardenafil, a potent and selective oral PDE5 inhibitor, is efficacious and generally well-tolerated in men with erectile dysfunction (ED).
Negative_regulation (inhibitor) of PDE5 associated with erectile dysfunction
6) Confidence 0.49 Published 2004 Journal The journal of sexual medicine Section Abstract Doc Link 16422971 Disease Relevance 0.10 Pain Relevance 0.04
To date, however, very little is known regarding the potential interaction between selective inhibitors of PDE 3, PDE 4 and PDE 5.
Negative_regulation (inhibitors) of PDE 5
7) Confidence 0.46 Published 2004 Journal Respir Res Section Body Doc Link PMC419478 Disease Relevance 0.46 Pain Relevance 0.15
In this present series of experiments, we have used sildenafil as the inhibitor of cGMP specific PDE 5.
Negative_regulation (inhibitor) of cGMP specific PDE 5
8) Confidence 0.46 Published 2004 Journal Respir Res Section Body Doc Link PMC419478 Disease Relevance 0.50 Pain Relevance 0.26
Interestingly, in an in vivo model of pulmonary resistance, the PDE 3 inhibitor, milrinone, and the PDE 5 inhibitor, zaprinast offer a synergistic effect when used in combination [27].
Negative_regulation (inhibitor) of PDE 5
9) Confidence 0.46 Published 2004 Journal Respir Res Section Body Doc Link PMC419478 Disease Relevance 0.41 Pain Relevance 0.17
Furthermore, there is evidence from knockout mice to explain the efficacy of PDE5 inhibitors in RE.
Negative_regulation (inhibitors) of PDE5 associated with targeted disruption
10) Confidence 0.43 Published 2004 Journal Drugs Section Abstract Doc Link 14723556 Disease Relevance 0.45 Pain Relevance 0.15
Available data indicate that there is clinical, anatomical, physiological, pharmacological and genetic evidence to explain the efficacy of PDE5 inhibitors in RE.
Negative_regulation (inhibitors) of PDE5
11) Confidence 0.43 Published 2004 Journal Drugs Section Abstract Doc Link 14723556 Disease Relevance 0.36 Pain Relevance 0.16
The rationale for the use of PDE5 inhibitors in the treatment of RE could be due to possible peripheral and central mechanisms.
Negative_regulation (inhibitors) of PDE5
12) Confidence 0.43 Published 2004 Journal Drugs Section Abstract Doc Link 14723556 Disease Relevance 0.36 Pain Relevance 0.16
An advantage of PDE-5 inhibitor over the endothelin receptor antagonists ambrisentan and bosentan, is that therapy with PDE-5 inhibitors does not require safety monitoring with monthly liver function tests.


Negative_regulation (inhibitor) of PDE-5 in liver associated with antagonist
13) Confidence 0.42 Published 2010 Journal Drug design, development and therapy Section Body Doc Link PMC2880338 Disease Relevance 0.78 Pain Relevance 0.05
For these reasons, inhibition of PDE-5 was hypothesized to serve as a viable target to enhance NO-mediated physiologic effects.17 The utility of PDE-5 inhibition in PAH was first demonstrated in 1991, when investigators successfully used the PDE-5 inhibitor zaprinast to mitigate alveolar induced hypoxia.18 Sildenafil, the first commercially available oral PDE-5 inhibitor, was studied in 2001 and demonstrated to prevent development of PH in hypoxic mouse models.19
Negative_regulation (inhibition) of PDE-5 associated with pulmonary hypertension and hypoxia
14) Confidence 0.42 Published 2010 Journal Drug design, development and therapy Section Body Doc Link PMC2880338 Disease Relevance 0.96 Pain Relevance 0
For these reasons, inhibition of PDE-5 was hypothesized to serve as a viable target to enhance NO-mediated physiologic effects.17 The utility of PDE-5 inhibition in PAH was first demonstrated in 1991, when investigators successfully used the PDE-5 inhibitor zaprinast to mitigate alveolar induced hypoxia.18 Sildenafil, the first commercially available oral PDE-5 inhibitor, was studied in 2001 and demonstrated to prevent development of PH in hypoxic mouse models.19
Negative_regulation (inhibition) of PDE-5 associated with pulmonary hypertension and hypoxia
15) Confidence 0.42 Published 2010 Journal Drug design, development and therapy Section Body Doc Link PMC2880338 Disease Relevance 0.94 Pain Relevance 0
Increased intracellular levels of cGMP were reported, suggesting that PDE5 inhibition restores sensitivity of pulmonary vascular to endogenous cGMP-dependent vasodilators.
Negative_regulation (inhibition) of PDE5
16) Confidence 0.42 Published 2010 Journal Drug design, development and therapy Section Body Doc Link PMC2880338 Disease Relevance 1.08 Pain Relevance 0.04
We hypothesize that nitric oxide synthase (NOS) uncoupling is important in the pathogenesis of interstitial lung disease-associated pulmonary hypertension, and this process can be abrogated by phosphodiesterase type 5 (PDE5) inhibition to improve pulmonary vascular remodeling and right ventricular function.
Negative_regulation (inhibition) of PDE5 in lung associated with pulmonary hypertension and interstitial lung diseases
17) Confidence 0.42 Published 2008 Journal Am. J. Physiol. Lung Cell Mol. Physiol. Section Abstract Doc Link 17965319 Disease Relevance 0.77 Pain Relevance 0.12
Sildenafil, an orally administered a phosphodiesterase type 5 (PDE-5) inhibitor, targets the NO pathway.
Negative_regulation (inhibitor) of PDE-5
18) Confidence 0.41 Published 2010 Journal Drug design, development and therapy Section Body Doc Link PMC2880338 Disease Relevance 1.27 Pain Relevance 0.07
Other PDE-5 inhibitors
Negative_regulation (inhibitors) of PDE-5
19) Confidence 0.36 Published 2010 Journal Drug design, development and therapy Section Body Doc Link PMC2880338 Disease Relevance 1.02 Pain Relevance 0
An advantage of PDE-5 inhibitor over the endothelin receptor antagonists ambrisentan and bosentan, is that therapy with PDE-5 inhibitors does not require safety monitoring with monthly liver function tests.


Negative_regulation (inhibitors) of PDE-5 in liver associated with antagonist
20) Confidence 0.36 Published 2010 Journal Drug design, development and therapy Section Body Doc Link PMC2880338 Disease Relevance 0.73 Pain Relevance 0.05

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox